The Group has posted a net profit after minority interest of Rs. 8880.50 mn for the Quarter ended March 31, 2015 where as the same was at Rs. 15871.20 million for the Quarter ended March 31, 2014.
Shares of Sun Pharmaceutical Industries was lower by 10% at Rs. 870 after the company posted Q4 results.
The stock has hit a high of Rs. 918 and a low of Rs. 870.
The Group has posted a net profit after minority interest of Rs. 8880.50 mn for the Quarter ended March 31, 2015 where as the same was at Rs. 15871.20 mn for the Quarter ended March 31, 2014.
Total Income is Rs. 65407.40 mn for the Quarter ended March 31, 2015 where as the same was at Rs. 42524.40 mn for the Quarter ended March 31, 2014.
Dilip Shanghvi, Managing Director of the Company said, “Post the completion of the merger, we have commenced the integration of Ranbaxy. Our performance has been impacted due to various one-time charges, mainly on account of the Ranbaxy merger as well as due to price erosion for some of our products in the US. It also reflects the impact of supply constraints related to the on-going remediation efforts at some of our facilities. We are pledged to being 100% cGMP compliant and are fully responsible towards our customers and patients across the world who rely on us for quality products.”
No comments:
Post a Comment